Key result
Sodium nitroprusside shows no benefit for bleeding, drainage, or clotting parameters after cardiac surgery.
Cohort (n=53)
Answers are grounded in this paper and cite their sources.
Retrospective review reveals no increase in blood loss with sodium nitroprusside in cardiac surgery patients, suggesting its safety for managing postoperative hypertension.
Sodium nitroprusside (SNP) is known to inhibit platelet aggregation and has been implicated in postoperative hemorrhagic complications. Because it is a useful agent for treating postoperative hypertension and low cardiac output in the cardiac surgical patient, the authors retrospectively reviewed the course of 53 patients undergoing open heart procedures on cardiopulmonary bypass. Twenty-three patients received SNP and 30 did not. There were no differences in baseline hematological or clotting profiles, liver functions, bypass or cross-clamping times or heparin/protamine requirements between the two groups. Analysis revealed no significant differences between the groups in blood product requirements, actual mediastinal drainage, or postoperative measurements of routine clotting parameters. Although biochemical inhibition of platelet aggregation can be demonstrated, the use of SNP in the cardiac surgical patient has no apparent clinical effects which sould detract from its utility in treating hypertension or low cardiac output.
No takes yet. Share an insight, caveat, or question.
Snow et al. (1981) conducted a cohort in Open heart surgery on cardiopulmonary bypass (n=53). Sodium nitroprusside vs. No sodium nitroprusside was evaluated on Blood product requirements, actual mediastinal drainage, and postoperative measurements of routine clotting parameters. Sodium nitroprusside use in 23 of 53 cardiac surgery patients resulted in no significant differences in blood product requirements, mediastinal drainage, or clotting parameters.
Synapse has enriched 10 related papers. Consider them for comparative context: